Author: trainitright

 

Guest Post on Personal Training: How to Begin a Regular Routine

 

Personal Training: How to Begin a Regular Routine

Wanting to get in shape? You should be commended for your determination. However, determination is nothing without discipline. If you want to actually get something out of exercise, it needs to fit into your schedule as easily as brushing your teeth. These tips will help you to begin a regular exercise routine.

Start Slowly

You’re probably feeling excited about starting a new exercise routine, and you should. However, burnout is a very real thing. If you’re doing three-hour runs from the beginning, you’re going to become exhausted. You want to be going as slowly as possible. That means you shouldn’t be exercising longer than your body allows, and you shouldn’t be using more weight than you’re prepared to.

Find a Good Gym

The beauty of exercise is that you can do it almost anywhere. That said, there’s no better place to get fit than at a quality gym. Look for ones in your area that will cater to your needs. If you are concerned about dealing with crowds, look for a 24-hour gym that allows you to visit at any hour of the day.

Get a Trainer

Don’t know where to start with your exercise routine? You don’t have to stumble around haphazardly. Instead, you should find yourself a dedicated trainer who can help you realize your exercise goals. Go to your gym and ask about their personal training program. You should be able to find someone who’s a good match. Be clear about your goals, whether they involve strength training, aerobics, or flexibility.

Keep a Gym Bag Around

After a long day at work or school, it can be difficult to summon the motivation to go to the gym. One of the easiest excuses you can make is that you don’t have your gym clothes with you. An easy fix to that is to keep your gym bag in your car or around your person.

Set Goals

The best way to stay motivated with an exercise routine is to regularly set goals that you can accomplish. These should be ones that are easy enough to accomplish, but challenging enough to actually give you a sense of drive and feeling of pride when accomplished. The further you go with your exercise routine, the more accomplished you’ll feel.

The benefits of exercise are so numerous, and we hope that you are inspired by this article to take charge of your body and your health. If you have already started or are planning on starting an exercise routine, remember to take everything one day and one step at a time.

Gym Grub: 4 Fast Food Meals You Can Still Eat While Trying to Stay in Shape

Eating fast food and staying fit doesn’t need to be mutually exclusive. While plenty of fast food is unhealthy, there are affordable and tasty options available to you. It’s just a matter of being willing to find them. Here are four fast food meals you can still eat while trying to stay in shape.

Chipotle Burrito Bowl

Going to Chipotle for a burrito bowl can be an ideal way to satisfy yourself after a workout. It’s important to make sure it’s a bowl and not a burrito. The caloriesfrom the flour tortilla can be significant. However, you can fit plenty of quality nutritional components in your burrito bowl, including beans, rice, and chicken.

Healthy Pizza

Pizza doesn’t need to be unhealthy. It can be a light and refreshing dish that still satisfies. What matter is how it’s prepared. You should opt for a thin crust with plenty of vegetables. Consider getting it without cheese to really save on calories. The next time you order pizza delivery, think about how you can make it healthier. You can still have a great dining experience with healthier pizza.

Subway Oven-Roasted Chicken Salad

Subway is widely associated with being healthy fast food. Not only do they have delectable sandwiches, they also have plenty of delicious saladsto choose from. One you should definitely consider ordering is their oven-roasted chicken salad. This is perfect for a power lunch as it will give you plenty of vitamins and protein. At less than 200 calories, you don’t have to feel any guilt about enjoying this meal either.

Chicken Sandwich

You’ll quickly learn that it’s best to avoid red meat when eating fast food. Thankfully, plenty of fast food chains have figured out ways to make delicious chicken sandwiches. You can find them at places such as KFC, Wendy’s, and Arby’s. Be sure to go easy on things like high-calorie condiments, such as mayo.

Fast food can be healthy and still satisfying. In fact, healthy fast food is arguably more satisfying, because you can enjoy it without guilt. Take a look at all these meals and think about which ones would work best for your tastes. It’s also important to be mindful of heavy sides like fries and the calories that can be avoided by getting water instead of soda. The joys of staying in shape should not be discounted, and you can determine your future, one meal at a time.

5 Fun Ways to Get that Healthy Body and Lifestyle You Have Always Wanted

 

There are many fun ways to get your body into shape and start living a healthier lifestyle. By adding some excitement to your fitness routine and healthy eating, you’ll have a better chance of sticking to your plan and achieving your goals. Here are five fun ways to get the body and lifestyle you’ve always wanted.

 

Just Dance

Dancing combines fitness and fun into one. When you move your body to some of your favorite tunes, you won’t even feel like you’re exercising. Dancing is great for burning calories, improving muscle tone and enhancing cardiovascular fitness. Whether you want to try swing, ballroom or hip-hop dancing, the possibilities are endless. To make your dance workouts even more exciting and productive, you can take group classes or private lessons.

 

Spice It Up

Eating healthy doesn’t always have to be bland. Adding some spices to your foods can give your taste buds more flavoring to enjoy. Most types of salsa contain very few calories and can be applied to foods liberally to improve their taste. Paprika, garlic and pepper can also make foods tastier to eat and won’t add a lot of extra fat and calories to your diet.

 

Join a Retreat

You can take part in a fitness retreatwhere you’ll be joined by other likeminded people in a supportive environment. Some of these retreats are held in remote areas that are surrounded by nature and free from many everyday distractions. During your time at the retreat, you’ll be able to connect with others and tackle emotional issues that often lead to engaging in unhealthy behaviors. You’ll also have the chance to take part in group fitness workouts and learn more about healthy nutrition.

 

Take a Hike

If you live near a mountain trail, a lake or some other nature area that has suitable conditions for walking, you can incorporate regular hikes into your fitness plan. You’ll have the chance to breathe in some fresh air and clear your mind while outdoors. As you improve your muscle coordination and stamina while hiking, you may also get the chance to see some charming wildlife creatures and other spectacular scenes of nature.NerdFitness.comsuggests going with a group of friends as often as possible to make hiking even more fun.

 

Play Active Videogames

Certain videogames require you to be on your feet and remain active in order to play them. Also known as exergames, these videogames encourage you to exercise while immersing yourself into a world of virtual reality. Many of these videogames involve dancing, playing tennis and engaging in other fun fitness activities. You may have to be hooked up to sensors and use other specialized equipment to play a game.

 

Becoming more fit doesn’t always have to be a hassle. By finding fun ways to live a healthier lifestyle, you’ll be on the road to g

Molecular Science Corp. Announces Receipt of Dealer's License from Health Canada

 

TORONTO, July 13, 2018 /CNW/ - Molecular Science Corp. ("MSC" or the "Company") is pleased to announce Molecular Science Labs Corp, a wholly owned subsidiary of MSC, has received a Dealer's License pursuant to the provisions of the Controlled Drugs and Substances Act and its Regulations from Health Canada.

Licensed activities will occur in MSC's state of the art lab facility located in Scarborough, Greater Toronto, Ontario, where cannabis samples can be received for the purpose of analytical testing.  MSC's lab services will include multiple analyses including pesticides, heavy metals, and potency in cannabis flower, cannabis oil extract and hemp.  This facility will implement processes in line with pharmaceutical industry best practices for analytical testing using high end LC-MS/MS, GC-MS/MS, ICP-MS and advanced automation systems.

"Achievement of this Dealers License allows MSC to continue on the path to providing the Canadian LPs with precise, efficient cannabis testing and product analysis in an effort to improve consumer safety as well as cultivation and extraction processes in line with Health Canada regulations," said Dr. Mauro Aiello, VP of Laboratory Operations and Product Development. "MSC is committed to improving the turn-around time, quality and reliability of analytical testing for the Cannabis industry through innovations in science, technology and efficient Quality Assurance processes. MSC's highly skilled team is implementing advanced methodologies and systems to achieve these goals."

About Molecular Science Corp.

MSC is a Canadian laboratory services company that will deliver analytical testing & data-driven business intelligence to the growing cannabis economy. The Company is dedicated to providing enterprise & craft-level Licensed Producers and Licensed Oil Processors the tools and services they require to succeed through accurate and timely testing of their products. Our brand new physical laboratory in Scarborough, Ontario will perform a series of analytical tests including potency, terpene profiling, pesticides, heavy metals and mycotoxins testing, as mandated by Health Canada's regulatory standards.  MSC is also bringing to market a mobile lab, custom built to provide an onsite pesticide testing solution to customers and to enable an interactive educational platform for product safety awareness, assisting producers in making informed decisions about their cultivation practices.

For more information visit mscience.ca

NOTICE REGARDING FORWARD LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law.  Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur.  These statements are only predictions.  Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release.  Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.  The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Regulatory authorities have not reviewed, approved or disapproved the contents of this press release.

SOURCE Molecular Science Corp

GeneNews' Innovative Diagnostic Laboratory Appoints David Byram Chief Commercial Officer

 

TORONTO, July 12, 2018 /CNW/ - GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) today announced the appointment of David Byram as the Chief Commercial Officer for its U.S. Lab, Innovative Diagnostic Laboratory, LLP ("IDL"). Mr. Byram will oversee all IDL's customer-facing activities including sales, client relations and commercial operations.

Mr. Byram is a senior commercial executive with over 25 years of pharmaceutical, biotechnology and medical device industry leadership experience. He has built successful product launches across multiple therapeutic areas that incorporate innovative sales and marketing strategies which have driven wide market adoption and revenue generation. Mr. Byram has broad health category experience including oncology/hematology, gastroenterology, rheumatology, neurology, cardiology and urology. During his career, Mr. Byram has overseen all commercial operations including sales and marketing, market access and pricing, channel strategy and new product development.  Prior to joining IDL, Mr. Byram was the Vice President, Commercial & Government Affairs for Braeburn Pharmaceuticals.  Prior to Braeburn, he held positions as SVP, Commercial Affairs for Orexo AB/US, US Director, Public Sector for Indivior plc, and Sr. Director, Strategic Accounts and Public Affairs for Janssen Biotech, a division of Johnson & Johnson. David is highly focused on delivering healthcare outcomes which create value for patients, physicians, payers and investors.

"We are extremely pleased to have David join IDL's senior leadership team," commented James R Howard-Tripp, Chairman and CEO of GeneNews. "With a very experienced executive to energetically manage the company's commercial operations and sales strategy, we can increase the pace of meeting our targeted sales objectives for 2018."

"It is an exciting time to be in the liquid biopsy space and I look forward to utilizing my commercialization expertise as well as prior sales experience in oncology and gastroenterology to support IDL's efforts to achieve our growth objectives and ensure the highest satisfaction of our clients," said Mr. Byram.

About GeneNews

GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease.

Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'.  More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar expressions, which reflect the Company's current expectations regarding future events, including with respect to the receipt of shareholder approval.  The forward-looking statements involve risks and uncertainties that could cause actual events to differ materially from those projected herein including the state of the equity capital markets, the receipt of required approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability of additional capital and the general business and political environment including in the healthcare sector. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

SOURCE GeneNews Limited

Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

 

Pivotal FLAURA study demonstrated 18.9 months median progression-free survival  for patients receiving Tagrisso versus 10.2 months compared with earlier generation EGFR tyrosine kinase inhibitors

MISSISSAUGA, ON, July 12, 2018 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Tagrisso® (osimertinib) for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations). Tagrisso has been granted a Notice of Compliance under Priority Review status based on data from the phase III FLAURA trial, which showed that patients who received first-line treatment of Tagrisso demonstrated 18.9 months median progression-free survival (PFS) versus 10.2 months in patients receiving earlier generation first-line EGFR tyrosine kinase inhibitors (TKI) erlotinib or gefitinib.i In addition, preliminary overall survival (OS) data from the study indicated a 37 per cent reduction in the risk of death (Hazard Ratio [HR] 0.63 at 25% maturity, not statistically significant as the OS data is still immature).ii

Until now, Tagrisso was approved as the only second-line treatment for patients with EGFR mutated NSCLC that progressed on EGFR-TKI treatment and whose tumour tested positive for the EGFR T790M mutation, the most common mutation acquired by resistance to TKI therapy.

For many patients with advanced EGFR mutated NSCLC, their first treatment is their only treatment. Today's announcement means that many more patients are now eligible to be treated earlier in their treatment journey with Tagrisso, a medicine that has been proven in a clinical study to provide almost nine months PFS benefits beyond that of earlier generation first-line EGFR TKI therapies.

More than half of all patients with EGFR mutated NSCLC will see the cancer spread to the central nervous system (CNS), including the brain, over the course of their disease. The development of CNS metastases leads to a poor prognosis and has a negative impact on quality of life. The FLAURA trial data demonstrated that PFS results for patients treated with first-line Tagrisso were consistent across all patient subgroups, including patients with or without CNS metastases. The FLAURA trial was the first and only study to demonstrate this level of efficacy in this difficult-to-treat patient population.iii

"The approval of Tagrisso in this first-line setting represents a major advancement in the treatment of EGFR mutated lung cancer," said Dr. Glenwood Goss, Professor of Medicine, University of Ottawa, and Director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre. "As an oncologist, I believe in using the best treatment first, and Tagrisso has shown to significantly extend progression-free survival and improve treatment of central nervous system metastases as a first-treatment of EGFR mutation positive non-small cell lung cancer. I am pleased to be able to offer this life-altering treatment as a first-line option to patients who need it."

The Health Canada approval of Tagrisso is based on the results of the phase III FLAURA trial. The trial assessed the efficacy and safety of Tagrisso 80mg once daily compared to earlier generation first-line EGFR-TKIs in previously untreated patients with locally advanced or metastatic EGFR mutated NSCLC.iv The trial was double-blinded and randomized, with 556 patients across 29 countries and demonstrated a statistically significant and clinically meaningful median PFS, 18.9 months for Tagrisso vs. 10.2 months for comparator (HR 0.46; 95% confidence interval [CI] 0.37, 0.57; p<0.001).v

Safety data for Tagrisso were in line with those observed in prior clinical trials.vi The treatment was well tolerated, with grade 3 or higher adverse events (AEs) occurring in 34 per cent of patients taking Tagrisso vs 45 per cent in the comparator arm.vii The most common adverse reactions (≥20%) in patients treated with Tagrisso were diarrhea (58%), rash or acne (58%), dry skin (36%), paronychia (35%), decreased appetite (20%) and stomatitis (29%).viii

Detailed results from the FLAURA trial are published online in the New England Journal of Medicine.ix

"The approval of Tagrisso as a first-line treatment is welcome news for lung cancer patients, for whom every day counts," said Shem Singh, Executive Director of Lung Cancer Canada. "Innovation in treatment offers hope against this difficult-to-treat disease and gives patients and their families a chance to spend more quality time together. This Health Canada approval is an important first step, and we call on all stakeholders to work together to ensure that Tagrisso in the first-line setting is publicly funded for all that need it."

About Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers), and the leading cause of death from cancer in Canada for both men and women.x On average, 78 Canadians are diagnosed with lung cancer every day and 58 Canadians will die from lung cancer each day.xi Lung cancer is a diverse disease which is often diagnosed at a late stage, making it difficult to treat.

There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which are determined by the type of cell in which the cancer starts.xii Non-small cell lung cancer is the most common form of lung cancer and accounts for 85 to 90 per cent of all lung cancers in Canada.xiii Often diagnosed in late stage, fewer than 17 per cent of patients with NSCLC will live more than five years following diagnosis.xiv Half of NSCLC cases are associated with known mutations.xv EGFR mutation occurs in approximately 10-35 per cent of NSCLC cases.xvi Most patients with EGFR mutated NSCLC progress following first-line treatment with approved TKIs within 9-12 months, due to acquired mutation resistance, of which the most common is EGFR T790M.xvii

About Tagrisso
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI designed to inhibit both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases. Tagrisso 40mg and 80mg once-daily oral tablets have been approved in Canada, the US, EU, Brazil and Russia for first-line EGFR mutated advanced NSCLC, and in more than 75 countries including Canada, the US, EU, Japan and China for patients in the second-line with EGFR T790M mutation-positive advanced NSCLC. Tagrisso is also being investigated in the adjuvant setting and in combination with other treatments.

Tagrisso was first approved with conditions by Health Canada (NOC/c) in July 2016 as the first and only medicine indicated for patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This was followed by a full approval as a second-line treatment in January 2018, based on the phase III AURA3 trial that demonstrated significant improvement in PFS with Tagrisso compared to chemotherapy.

In May 2017, Tagrisso in the second-line setting received a positive clinical recommendation for reimbursement by the pan-Canadian Oncology Drug Review (pCODR).

AstraZeneca is committed to working with the pan-Canadian Pharmaceutical Alliance (pCPA), provinces and territories to ensure that Tagrisso is made publicly available as soon as possible for appropriate patients in both the first and second-line settings. For patients, there is no time to wait.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our AstraZeneca Canada headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.

References
_________________________________
i AstraZeneca Canada Inc., Tagrisso® (osimertinib), Product Monograph. July 2018.
ii Ibid.
iii Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125
iv Ibid.
v Ibid.
vi Ibid.
vii Ibid.
viii Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125
ix Ibid.
x Canadian Cancer Society. Lung Cancer Statistics. Accessed July 6, 2018. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=pe
xi Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at:  http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf
xii Ibid.
xiii Molina JR, et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 2008 May; 83(5): 584-594.
xiv Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at:  http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf
xv Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis. Oct 2013;5 Suppl 5:S579-592.
xvi Dong, Lijun, Dan Lei, and Haijun Zhang. "Clinical Strategies for Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer Patients." Oncotarget 8.38 (2017): 64600–64606. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610029/
xvii Mazza, Valentina, and Federico Cappuzzo. "Treating EGFR Mutation Resistance in Non-Small Cell Lung Cancer – Role of Osimertinib." The Application of Clinical Genetics 10 (2017): 49–56. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536882/

 

SOURCE AstraZeneca

CNW Group Ltd

MedReleaf to Sponsor Cancer Trial in Collaboration with the Ontario Clinical Oncology Group

In affiliation with Hamilton Health Sciences and the Department of Oncology at McMaster University  

MARKHAM, ON, July 12, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil.

The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients with cancer related pain will be administered MedReleaf's uniquely formatted cannabis oil capsules with the objective of improving pain management.

Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.

"Patients with cancer often suffer from significant pain and we know that while managing the pain with narcotics is often necessary, it is also fraught with issues," said Dr. Marissa Slaven. "Anecdotally, cancer patients have been telling us that cannabis products help their pain. Thanks to MedReleaf's commitment to advancing medical science we will now be able to start gathering the data needed to help our patients live better."

"Collaborating with the Ontario Oncology Group under the direction of Dr. Levine and its affiliates speaks to MedReleaf's foundation as an R&D driven company," said Neil Closner, CEO MedReleaf. "We are thrilled to have the opportunity to be involved in this important cancer trial which has the potential to positively impact the lives of cancer patients while advancing our understanding of the therapeutic benefits of medical cannabis and validating new treatment options for patients."

About OCOG

OCOG is an academic trials group based in the Escarpment Cancer Research Institute, a joint research institute of Hamilton Health Sciences and McMaster University. OCOG works with networks of investigators to design and conduct cancer clinical trials provincially, nationally, and beyond. OCOG was established in 1982 and since then over 12,000 patients have been entered in OCOG studies. The results of which have impacted on clinical care.

For more information on this and other cancer clinical trials, please visit www.ocog.ca

About MedReleaf Corp.

Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit www.medreleaf.com or follow @medreleaf

SOURCE MedReleaf Corp.

Jersey Shore's Vinny Guadagnino joins
star-studded talent lineup at
25th annual canfitpro World Fitness Expo
Media accreditation still open for the world’s largest fitness education event at the Metro Toronto Convention Centre August 8-12

TORONTO, ON — canfitpro announced today MTV reality star Vinny Guadagnino will join headliners Derek Hough of World of Dance and celebrity trainer, Jillian Michaels, at the 2018 World Fitness Expo this August. Fitness enthusiasts and industry professionals alike will get a chance to preview the latest trends at the world’s largest fitness conference and trade show. Now in its milestone 25th year, the Expo returns to the Metro Toronto Convention Centre from August 8-12 to entertain thousands with world-renowned workouts and education seminars.

Vinny Guadagnino
Rising to fame on the MTV hit reality series Jersey Shore, which ran for six seasons from 2009-2012 and is the highest rated series in MTV’s history, Vinny now stars in its reboot series, Jersey Shore Family Vacation. In addition to reality TV stardom, he is a New York Times bestselling author, actor and activist. At World Fitness Expo, Vinny will be taking part in a Q&A and Meet & Greet, sharing his story of fitness, nutrition and overcoming social anxiety.

Additional notable talent joining the event this year include:

  • Billy Blanks – Creator of the revolutionary Tae Bo Fitness® workout
  • Derek Hough – Star of NBC’s World of Dance
  • Jillian Michaels – Reality TV star and creator of BODYSHRED™
  • The Brutez – The dancing bodybuilders with an electrifying and intensely effective style
  • Thomas Delauer – One of the world’s leading experts on the keto diet and intermittent fasting
  • Tosca Reno – Bestselling author of the Eat-Clean diet
  • Vikram Vij – Restaurateur, cookbook author and former Dragon’s Den judge

Attendees can choose from a variety of educational sessions presented by industry experts and workouts lead by the world’s top fitness superstars.  For additional activities, contests and exhibitor prizes, guests can visit Expo Hall, open August 10 and 11. General admission tickets to Expo Hall can be purchased online for $17.70.

Media can apply for accreditation at worldfitnessexpo.com/media-credentials.

Website: www.worldfitnessexpo.com
Twitter: @canfitpro
Instagram: @canfitpro
Facebook: @canfitpro
Hashtag: #canfitpro #worldfitnessexpo

About canfitpro
canfitpro is the largest provider of education in the Canadian fitness industry. Founded in 1993, canfitpro delivers accessible, quality education, certifications, events and membership services. canfitpro's over 24,000 members include some of the world's finest fitness professionals, health club operators, industry suppliers, and fitness consumers.

WHAT: Yesterday evening, SPINCO surprised guests at their 4th birthday party with a performance by Loud Luxury at REBEL. The Canadian DJ duo set the tone for SPINCO's largest ride ever, providing upbeat music including their popular single, 'Body'.

 

WHEN: Wednesday, July 11, 2018

WHERE: REBEL (11 Polson Street)

PHOTO LINK: http://bit.ly/2upK2EF

PHOTOGRAPHER: Arthur Mola

VIDEO LINK: http://bit.ly/2mb2xZN

HANDLES: @SPINCOToronto | #TeamSPINCO | #SPINCOTurns4

 

NOTES: SPINCO hosted a 100+ person spin class in support of Right To Play as a special thank you to their community of riders and supporters for an amazing four years.

SPINCO's_4th_Birthday_July-11,2018-34 (1).jpg

LELO summer tips : Challenge accepted: Surviving Summer Festival Season

Hello,

You got the tickets ages ago, finally settled on the perfect outfit, prepped your selfie stick and so the only thing left is to show up and slay the summer festival scene. But as most of you already know - that's easier said than done.

It's the same tired old story every year -  you planned everything down to the most minute detail and counted down the days until you could finally stand in front of your favorite band. You couldn't wait to blow off some steam and dance your heart out until the break of dawn, but… But. But something came up again - it started raining, you got separated from your friends, of course, the cell-reception is poor, you look like you rolled around in a giant beer puddle… You know, the usual.

The secret to having a good time at any festival, unencumbered by worries such as “I stink like a wet dog” or “I will die of thirst right this second” or “Is this condom still okay even though I had it for 5 years?” rests in detailed planning. By using a couple of more grey cells than usual, you'll successfully avoid dealing with crisis upon crisis and manage to enjoy yourself to the fullest. Yes, it makes the whole thing a whole lot less spontaneous, but it's totally worth it.

In order to save you some time and because we've all been there, here is some useful advice that will get you on the right track to the best time of your life:

1. Play by the rules.

Yes, it's very chic to be a rebel, but having to throw away that expensive perfume bottle you spent waaay too much on because you can't have it on festival grounds definitely does not fall under the chic category. It's just dumb. And very sad. Every festival website has the list of items that aren't allowed on the grounds. Read it and pack accordingly. Also, make sure to hit that ATM. Most places have a one-time-entrance-only policy which means you'll be stranded and at the mercy of festival economy with no money.

2. Water definitely isn't the life of the party, but without it, you won't be either.

You won't be able to get your water bottle past the security guards, so as soon as you enter, make a beeline for the first bar and get a couple of waters. Stuff them in your trusty festival backpack (a must-have), then happily order your spirit of choice. Water will save you from the merciless summer heat, and if you drink enough of it, it might even spare you from a raging hangover the following morning.

3. Pack smart and dress in layers.

Luckily, boho is always in during festival season. Make sure your outfit consists of several practical pieces that will see you through all weather conditions - rain, shine or beer spray from overzealous partiers. Focus on natural fabrics that will let your skin breathe freely (no more Eau De Wet Dog) and bring a spare shirt and a spare pair of socks. Throw away that decade-old condom and get a new one. This might be the year you finally get lucky.

4. Go analog with your meetup plans.

Think back to any concert you've been to in the past. It got pretty loud, didn't it? To avoid excess wandering and frustrating attempts to make a phone call while waving your hands in the air like an idiot who didn't care to make proper contingency plans, set up a meetup spot in case you get separated from your friends. Try to be as precise as possible. “Meet me by the beer stand” isn't precise when there are 20 of them lying around.

5. Wet-wipes are more than baby bum cleaners.

You'll thank us after your first encounter with the toilet. Plus they're handy at getting that cheap beer smell out of your skin.

6. Stay safe and play safe.

Yes, we know it's summer and you just want to lie back and enjoy yourself. The outside world kind of fades away the moment you step onto the festival grounds and every single one of us turns into a glutton for the good times. LELO, the world's leading pleasure brand and a big advocate of the good times, wants you to make an effort and enjoy yourself responsibly. That kind of sounds like a big fat oxymoron but it makes perfect sense, just let us explain. It's really hard not to let go and enjoy the moment once the rhythm sets in. You're ready to give in and let yourself get carried away by the pulsating lights and undulating bodies and trust that all seems right with the world. Consequences? Adulthood? Responsibilities? Pish, it's summer! Remember those shiny new condoms you bought? If you treated yourself with LELO HEX condoms, it'll only take a second to slip one on, let go and completely forget that it's there. Responsible enjoyment? Doesn't seem like a longshot after all.